
Stem Cell Banking Market based on By Cell Type (Umbilical Cord Stem Cells, Adult Stem Cells, Embryonic Stem Cells), By Bank Type (Private Banks, Public Banks, Hybrid Banks) and By Application (Thalassemia, Cerebral Palsy, Diabetes, Leukemia, Autism),Regi
Description
The increased awareness of stem cell banking's medicinal potential is driving the market CAGR. As more clinical evidence becomes accessible, public awareness of stem cell therapeutic potential grows. Furthermore, stem cells have been shown to effectively cure over 80 illnesses and ailments, including cancer, degenerative neuromuscular disorders, metabolic disorders, immune deficiency diseases, and haemophilia. During the study period, it is expected that public awareness and adoption of stem cell therapies and stem cell banking services will increase as per capita disposable income in developing countries continues to rise and the costs of the products associated with these treatments fall. In the cell banking outsourcing business, cells, cell lines, and tissues are maintained, collected, evaluated, and characterised to guarantee minimal adverse effects and maximum efficacy while developing R&D activities and biopharmaceuticals. However, the costly expense of keeping these cells in cell banks is a significant hurdle for this sector. Several legal considerations surrounding stem cell banking and other kinds of cell banking are expected to hinder the business.
One stage in constructing the cell bank is careful cryopreservation of the cells. The biology of the cell line being frozen, the freezing medium employed, and the freezing or freeze profile technique are the three most essential aspects determining cryopreservation quality. The size of the cell bank has a significant impact on the quality of cryopreservation since a smaller or bigger bank may experience more vial-to-vial variability due to temperature changes, handling idiosyncrasies, and timing variations. The rising demand for stem cell therapies is one of the primary factors driving the market's rise. Stem cell applications in cell therapy, regenerative medicine, drug discovery, toxicity, and developmental biology research are very promising for preserving their biological characteristics, preventing contamination and deterioration, and enabling their effective use in fundamental and translational research and current and future therapeutic applications.
One stage in constructing the cell bank is careful cryopreservation of the cells. The biology of the cell line being frozen, the freezing medium employed, and the freezing or freeze profile technique are the three most essential aspects determining cryopreservation quality. The size of the cell bank has a significant impact on the quality of cryopreservation since a smaller or bigger bank may experience more vial-to-vial variability due to temperature changes, handling idiosyncrasies, and timing variations. The rising demand for stem cell therapies is one of the primary factors driving the market's rise. Stem cell applications in cell therapy, regenerative medicine, drug discovery, toxicity, and developmental biology research are very promising for preserving their biological characteristics, preventing contamination and deterioration, and enabling their effective use in fundamental and translational research and current and future therapeutic applications.
Table of Contents
148 Pages
- 1. Executive Summary
- 2. Industry Outlook
- 2.1. Industry Overview
- 2.2. Industry Trends
- 3. Market Snapshot
- 3.1. Market Definition
- 3.2. Market Outlook
- 3.2.1. Porter Five Forces
- 3.3. Related Markets
- 4. Market characteristics
- 4.1. Market Overview
- 4.2. Market Segmentation
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. DRO - Impact Analysis
- 5. Cell type: Market Size & Analysis
- 5.1. Overview
- 5.2. Umbilical Cord Stem Cells
- 5.3. Adult Stem Cells
- 5.4. Embryonic Stem Cells
- 6. Bank type: Market Size & Analysis
- 6.1. Overview
- 6.2. Private Banks
- 6.3. Public Banks
- 6.4. Hybrid Banks
- 7. Application: Market Size & Analysis
- 7.1. Overview
- 7.2. Thalassemia
- 7.3. Cerebral Palsy
- 7.4. Diabetes
- 7.5. Leukemia
- 7.6. Autism
- 8. Geography: Market Size & Analysis
- 8.1. Overview
- 8.2. North America (U.S., Mexico, Canada)
- 8.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
- 8.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
- 8.5. Latin America (Brazil, Argentina)
- 8.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
- 9. Competitive Landscape
- 9.1. Competitor Comparison Analysis
- 9.2. Market Developments
- 9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
- 9.2.2. Product Launches and execution
- 10. Vendor Profiles
- 10.1. TRINA SOLAR (CHINA)
- 10.1.1. Overview
- 10.1.2. Financial Overview
- 10.1.3. Product Offerings
- 10.1.4. Developments
- 10.1.5. Business Strategy
- 10.2. FIRST SOLAR (U.S.)
- 10.2.1. Overview
- 10.2.2. Financial Overview
- 10.2.3. Product Offerings
- 10.2.4. Developments
- 10.2.5. Business Strategy
- 10.3. YINGLI SOLAR (CHINA)
- 10.3.1. Overview
- 10.3.2. Financial Overview
- 10.3.3. Product Offerings
- 10.3.4. Developments
- 10.3.5. Business Strategy
- 10.4. TATA POWER SOLAR SYSTEM LTD (INDIA)
- 10.4.1. Overview
- 10.4.2. Financial Overview
- 10.4.3. Product Offerings
- 10.4.4. Developments
- 10.4.5. Business Strategy
- 10.5. ABENGOA (SPAIN)
- 10.5.1. Overview
- 10.5.2. Financial Overview
- 10.5.3. Product Offerings
- 10.5.4. Developments
- 10.5.5. Business Strategy
- 10.6. CANADIAN SOLAR INC. (CANADA)
- 10.6.1. Overview
- 10.6.2. Financial Overview
- 10.6.3. Product Offerings
- 10.6.4. Developments
- 10.6.5. Business Strategy
- 10.7. WAAREE GROUP (INDIA)
- 10.7.1. Overview
- 10.7.2. Financial Overview
- 10.7.3. Product Offerings
- 10.7.4. Developments
- 10.7.5. Business Strategy
- 10.8. GENERAL ELECTRIC COMPANY (U.S.)
- 10.8.1. Overview
- 10.8.2. Financial Overview
- 10.8.3. Product Offerings
- 10.8.4. Developments
- 10.8.5. Business Strategy
- 10.9. SUNPOWER CORPORATION (U.S.)
- 10.9.1. Overview
- 10.9.2. Financial Overview
- 10.9.3. Product Offerings
- 10.9.4. Developments
- 10.9.5. Business Strategy
- 10.10. URJA GLOBAL LIMITED (INDIA)
- 10.10.1. Overview
- 10.10.2. Financial Overview
- 10.10.3. Product Offerings
- 10.10.4. Developments
- 10.10.5. Business Strategy
- 11. Analyst Opinion
- 12. Annexure
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.